This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Subscribe To Our Newsletter & Stay Updated
